Table 1.

Primers used in this study

Primer name	Sequence (5′-3′)	Length (bp)
pGL3 forw	CGGGCGCGGTCGGTAAAGT	380
pGL3 rev	AACAACGGCGGCGGGAAGT
p16 forw	GCCACTCTCACCCGACCCGT	130
p16 rev	TCAGCCAGGTCCACGGGCAGA
ITGA6 forw	GCCAGCAAGGTGTAGCAGCTA	101
ITGA6 rev	TTGCTCTACACGAACAATCCCTTT
SDC1 forw	CCCCGTTTCTGGTGGTCT	175
SDC1 rev	TGTCTGAAGGCTGAGTCCC
CD21 forw	GCCGACACGACTACCAACC	150
CD21 rev	AGCAAGTAACCAGATTCACAGC
IL8 forw	GAGAGTGATTGAGAGTGGACCAC	111
IL8 rev	CACAACCCTCTGCACCCAGTTT
IL6	SABiosciences (PPH00560B)	160
IL12A	SABiosciences (PPH00544B)	82
IFNGR1	SABiosciences (PPH00871B)	112
TNFA1P1	SABiosciences (PPH01176A)	101
GAPDH forw	GGCTCTCCAGAACATCATCC	192
GAPDH rev	GCCTGCTTCACCACCTTC
MY09a, b	CGTCCMARRGGAWACTGATC	452
MY11	GCMCAGGGWCATAAYAATGG
GP5+	TTTGTTACTGTGGTAGATACTAC	150
GP6+	GAAAAATAAACTGTAAATCATATTC
EBV-P23-1	CAGCTCCACGCAAAGTCAGATTG	482
EBV-P23-2	ATCAGAAATTTGCACTTTCTTTGC
EBV-P23-3	TTGACATGAGCATGGAAGAC	363
EBV-P23-4	CTCGTGGTCGTGTTCCCTCAC
β-actin forw	ATCATGTTTGAGACCTTCAA	320
β-actin rev	CATCTCTTGCTCGAAGTCCA

^a M, A+C: R, A+G; W, A+T; Y, C+T;

^b degenerate primers targeting the HPV late structural protein L1.